Suggested remit: To appraise the clinical and cost effectiveness of avelumab within its marketing authorisation for treating non-small-cell lung cancer after platinum-based chemotherapy.
Referred February 13 2018
Status Suspended
Decision Selected
Process STA 2018
ID number 1146

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
17 January 2020 The Department for Health and Social Care has asked NICE to carry out an appraisal of avelumab for treating non-small-cell lung cancer after platinum-based chemotherapy For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
17 January 2020 Suspended. Referred February 13 2018
25 April 2018 - 24 May 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
13 February 2018 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual